{
    "clinical_study": {
        "@rank": "83791", 
        "arm_group": [
            {
                "arm_group_label": "Carboxymethylcellulose Based Eye Drop Formulation A", 
                "arm_group_type": "Experimental", 
                "description": "Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days."
            }, 
            {
                "arm_group_label": "OPTIVE\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE\u2122) 1-2 drops in each eye as needed at least 2 times daily for 90 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of a carboxymethylcellulose based eye drop\n      formulation compared with carboxymethylcellulose based preservative-free lubricant eye drops\n      (OPTIVE\u2122) in subjects with dry eye disease."
        }, 
        "brief_title": "A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE\u2122 in Subjects With Dry Eye Disease", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Disease", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Eye Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have used artificial tears for dry eye\n\n        Exclusion Criteria:\n\n          -  Start date of over the counter, herbal, prescription or nutritional supplements that\n             may affect dry eye or vision within 3 months prior to study start or an anticipated\n             change in dosage during the study\n\n          -  History of eye surgery or trauma in the 6 months prior to study start\n\n          -  Current use or use within 2 weeks of study start, of topical eye medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "461", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664949", 
            "org_study_id": "11002X-001", 
            "secondary_id": "2012-002238-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carboxymethylcellulose Based Eye Drop Formulation A", 
                "description": "Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.", 
                "intervention_name": "Carboxymethylcellulose Based Eye Drop Formulation A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "OPTIVE\u2122", 
                "description": "Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE\u2122) 1-2 drops in each eye as needed at least 2 times daily for 90 days.", 
                "intervention_name": "Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops", 
                "intervention_type": "Drug", 
                "other_name": [
                    "REFRESH OPTIVE\u2122", 
                    "OPTAVA\u2122"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Carboxymethylcellulose Sodium"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours Cedex", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huelva", 
                        "country": "Spain"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United Kingdom", 
                        "state": "England"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "state": "Hampshire"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "France", 
                "Germany", 
                "Italy", 
                "Russian Federation", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Ocular Surface Disease Index (OSDI) Score at day 90", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 90"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664949"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tear Break-up Time", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Corneal Staining", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Conjunctival staining", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Schirmer test", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}